REFERENCES
- Paramore A, Frantz S. Bortezomib. Nat Rev 2003;2:611 —612.
- Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bc1-xL overexpressing cells. Oncogene 2002;22:4953 —4963.
- Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Apoptotic signaling induced by immunomodulatory thalido-mide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525— 4530.
- Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Chin Cancer Res 2003;9: 6316 — 6325.
- Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD, Goldschmidt H. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001;98:3846–3848.
- Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
- Zangari M, Barlogie B, Jacobson J, Rasmussen E, Burns M, Kordsmeier B, Shaughnessy JD, Anaissie EJ, Thertulien R, Fassas A, et al. VTD regimen comprising velcade (V) + thalidomide (T) and added DEX (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood 2003;102:236a.